Industria y Comercio
SUPERINTENDENCIA

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 00-001451- -00020-0005
Fecha: 2010-09-20 15:40:19 Dep: 2020 DIR.NUEVASCR
Tra. 2 PATENTES Eve 2 TRANSFEREN
Act 411 PRESENTACION Folios: 52

FORMULARIO ÚNICO DE INSCRIPCION DE APLICACIONES

1.

- [X] Patente de Invención.
- [ ] Patente de Modelo de Utilidad
- [ ] Diseño Industrial
- [ ] Esquema de Trazado de Circuitos Integrados.
- [ ] Marcas de Productos o Servicios.
- [ ] Marca Colectiva.
- [ ] Marca de Certificación
- [ ] Lema Comercial.
- [ ] Nombre Comercial
- [ ] Enseña Comercial

2.

- [X] Transferencia
- [ ] Cambio de domicilio
- [ ] Prendas
- [ ] Modificación o limitación a reivindicar
- [ ] Cambio de nombre
- [ ] Cambio de dirección
- [ ] Embargos

3 SOLICITANTE (71)

Nombre: **Bayer Health Care LLC.**

Dirección: 555 Whire Plains Road, Tarrytown, New York 10591, Estados Unidos de América.
Nacionalidad o Domicilio: Tarrytown, New York, Estados Unidos de América.
Lugar de Constitución: Delaware, Estados Unidos de América.

Teléfono : Fax:
E-mail:

IDENTIFICACIÓN

C.C. [ ] **NIT** [ ]
C.E. [ ] **Otro** [ ]
Cual _____
Número _____

4 REPRESENTANTE O APODERADO

Nombre: DILIA MARIA RODRIGUEZ D´ALEMAN

Dirección: Cra. 11 No. 86-53 piso 6

Teléfono: 6 162051/61 Fax: 6 161889

E-mail: clarkemodet@clarkemodet.com.co

IDENTIFICACIÓN

C.C. [X] NIT [ ]
C.E. [ ] Otro [ ]
Cual

Número 41.654.882 T.P. **20824**

5 Titulo de la nueva creación o denominación del signo distintivo:

DIFENIL UREAS SUSTITUIDAS CON W-CARBOXIARILO Y SUS SALES FARMACEUTICAMENTE ACEPTABLES COMO INHIBIDORES DE RAF QUINASA.

Clasificación A 61 K 31/19 Número de expediente o certificado **00-001.451**

Número de expediente o certificado de registro de marca asociada (si es lema): _____
Vigencia:

TRANSFERENCIA

De: Bayer Corporation
Domicilio: 100 Bayer Road, Pittsburg, Pennsylvania 15205, Estados Unidos de América.

A: **Bayer Health Care LLC.**
Domicilio: **555 Whire Plains Road, Tarrytown, New York 10591, Estados Unidos de América.**

CAMBIO DE NOMBRE

De: _____

A: _____

CAMBIO DE DOMICILIO

De: _____

A: _____

906

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 10 - 63,174
FECHA : AGOSTO 3 DE 2010

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 00-001451--00020-0005
Fecha. 2010-09-30 15:40:19 Doc: 2020 DIR.NUEVASCR
Tra 2 PATENTES Cue 2 TRANSFEREN
Act 411 PRESENTACION Folios: 02

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET	CONSIGNACION	BANCO DE BOGOTA	062754387	380476084	02/08/2010	94,210,000.00

***** C O N C E P T O *****

CANT.	RENTISTICO	CONCEPTO		TOTAL CONCEPTO
1	50005-01-09 OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVCIOS ADMINISTRATIVOS		200,000.00
		TOTAL :	$	200,000.00

SON: DOSCIENTOS MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA COMO PARTE DE LA CANCELACION DE UNA TARIFA VISENTE Y NO PODRA SER SUSTITUIDA POR NINGUN RECIBO.

2

P-291

907

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 10 - 71,223
FECHA : AGOSTO 27 DE 2010

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 00-001451--00020-0005
Fecha: 2010-09-20 15:40:15 Dep: 2020 DIR.NUEVASCR
Tar: 2 PATENTES Cve: 2 TRANSFEREN
Sol: 411 PRESENTACION Folios: 52

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET	CONSIGNACION	BANCO DE BOGOTA	062754387	353156554	26/08/2010	85,505,000.00

***** C O N C E P T O *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09 OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVCIOS ADMINISTRATIVOS	50,000.00
		TOTAL : $	50,000.00

SON: CINCUENTA MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER SUSTITUIDA POR NINGUN RECIBO.

3

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 10 - 71,273
FECHA : AGOSTO 27 DE 2010

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 00-001451- -00020-0005
Fecha: 2010-09-20 15:40:19 Dep: 2020 DIRNUEVASCR
Cla: 2 PATENTES Sub: 2 TRANSFEREN
Act: 411 PRESENTACION Folios: 52

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET	CONSIGNACION	BANCO DE BOGOTA	062754387	353156554	26/08/2010	85,505,000.00

***** C O N C E P T O *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09 OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVCIOS ADMINISTRATIVOS	20,000.00
		TOTAL : $	20,000.00

SON: VEINTE MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER SUSTITUIDA POR NINGUN RECIBO.

4

908

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

CERTIFICACION DE EXCEDENTE : 10 - 63,303
FECHA : AGOSTO 3 DE 2010

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
No. 00-001451- -00020-0005
Fecha: 2010-09-06 15:40:19 Doc: 2020 DIR NUEVA SOR
Ing: 3 PATENTES Sve: 2 TRANSFEREN
Act: 411 PRESENTACION Folios: 52

***** C O N S I G N A C I O N *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CLARKE MODET	CONSIGNACION	BANCO DE BOGOTA	062754387	380476084	02/08/2010	94,210,000.00

***** C O N C E P T O *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-09 OTROS SERVICIOS DE PROPIEDAD I	99 OTROS SERVCIOS ADMINISTRATIVOS	10,000.00
		TOTAL : $	10,000.00

SON: DIEZ MIL PESOS

RESPONSABLE : _____

RECIBO DE CAJA APLICADO AL EXPEDIENTE No._____

ESTA CERTIFICACION DE EXCEDENTE DE PAGO SOLO PODRA SER UTILIZADA COMO PARTE DE LA CANCELACION DE UNA TARIFA VIGENTE Y NO PODRA SER SUSTITUIDA POR NINGUN RECIBO.

5

Traducción oficial hecha por Jimena Escobar Uribe, traductora e intérprete oficial según resolución No. 0369 de 1995 del Ministerio de Justicia, del documento legalizado mediante la **APOSTILLA** No. **A-118100C** de 12 de agosto de 2010 expedida en Estados Unidos de América (Nueva York) correspondiente a un documento de poder en inglés con idéntico texto en español (razón por la cual no se hace su traducción) otorgado por la sociedad **BAYER HEALTH CARE LLC.**, domiciliada en Tarrytown, Nueva York, Estados Unidos de América.

Documento de poder otorgado en relación con la solicitud de patente No. 00001451, patente No. 28604, titulada "ω-carboxilar sustituido difenil ureas como inhibidores raf quinasa", firmado el 28 de julio de 2010 en Tarrytown, Nueva York, Estados Unidos de América por R. Scott Meece, Abogado General, Vicepresidente senior, Secretario y Funcionario Autorizado.

Certificado notarial:
En este día 28 de julio de 2010, yo, Paula A. Harney, certifico que R. Scott Meece personalmente compareció ante mí, probó a través de evidencia satisfactoria que él es la persona cuyo nombre está firmado en el instrumento precedente o anexo y reconoció ante mí que él ejecutó el mismo en su capacidad autorizada como Abogado General y Secretario de Bayer HealthCare LLC, domiciliado en 555 White Plains Road, Tarrytown, Nueva York, 10591, Estados Unidos y la cual es una sociedad con vigencia legal, constituido y existente de acuerdo con las leyes de Delaware, que funcionarios de Bayer HealthCare LLC tienen poder para firmar documentos en nombre de Bayer HealthCare LLC de acuerdo con resoluciones adoptadas en la reunión de la Junta Directiva llevada a cabo el 16 de

JIMENA ESCOBAR URIBE
Traductor e Intérprete Oficial

abril de 2003 y que por su firma en el instrumento él, o la entidad a nombre de la cual él actuó, ejecutó el instrumento.

Estados Unidos de América
Estados de Nueva York

Condado de Westchester
Firmado: Paula A. Harney, notario público
Sello: Paula A. Harney, notario público, Estado de Nueva York, No. 4899023, calificada en el condado d Westchester, mi comisión termina el 6 de julio de 2011

****

Estado de Nueva York
Condado de Westchester

Yo, **Timothy C. Idoni**, Escribano del Condado de Westchester y Escribano de la Suprema Corte y Corte del Condado en y para dicho Condado, siendo las mismas cortes de registro tendiendo un sello, POR MEDIO DEL PRESENTE CERTIFICO que **Paula A. Harney**, cuyo nombre está suscrito en la declaración juramentada, declaración, certificado de reconocimiento o prueba del instrumento anexo, era al momento de tomar el mismo un NOTARIO PÚBLICO en y para el Estado de Nueva York debidamente comisionado, juramentado y calificado para actuar como tal en el Condado de Westchester y a lo largo de dicho Estado; que de acuerdo con la ley, una comisión un certificado de su carácter oficial y una firma autografiada de dicho NOTARIO PÚBLICO han sido presentados en mi oficina; que dicho NOTARIO PÚBLICO estaba debidamente autorizado por las leyes del Estado de Nueva York para administrar juramentos y afirmaciones, para certificar todos los reconocimientos de prueba de escrituras y otros instrumentos

Circulo de ... Notary Public ... Certificate that this ... FOTOCOPIA ... Conforme con su Original ... 2010 ... NOTARIO PUBLICO

escritos para tierras, tenencias y herencias a ser leídas en evidencia o registrado en dicho Estado, para protestar notas y tomar y certificar declaraciones juramentadas; ; y que estoy bien familiarizado con la escritura de dicho NOTARIO PÚBLICO o he comparado la firma de dicho Notario Público en el instrumento anexo con la firma autografiada de dicho Notario Público depositada en mi oficina y creo que la firma en el instrumento anexo es auténtica.

No se requiere un sello notarial por las leyes del Estado de Nueva York.

EN TESTIMONIO DE LO CUAL, he firmado aquí y puesto mi sello oficial este día 9 de agosto de 2010

Firmado: Firma ilegible
Escribano del Condado y Escribano de la Corte Suprema y Corte del Condado, Westchester, Nueva York

****


APOSTILLA

(Convención de la Haya de 5 de octubre de 1961)

1. País: Estados Unidos de América
Este documento público
2. ha sido firmado por Timothy C. Idoni
3. Actuando en su calidad de Escribano del Condado
4. Lleva el sello/estampilla del Condado de Westchester

CERTIFICADO

5. En Albany, Nueva York
6. el día 12 de agosto de 2010



912

JIMENA ESCOBAR URIBE
Traductor e Intérprete Oficial
Resolución No. 0369 Min. Justicia 1995

7. Por el Secretario de Estado, Estado de Nueva York

8. No. A-118100C

9. Sello/Estampilla: Estado de Nueva York, Departamento de Estado

10. Firma: Firmado por Lorraine Cortés-Vázquez
Secretario de Estado

Como Notario Once del Círculo de Bogotá D.C. hago constar que esta FOTOCOPIA concuerda con su Original que me fue presentado a la vista

SEP 2010

Guillermo Chávez Castañeda
NOTARIO ONCE
BOGOTA D.C.

9

913

Apostille

(Convention de La Haye du 5 Octobre 1961)

1. Country: United States of America

This public document

2. has been signed by **Timothy C. Idoni**

3. acting in the capacity of **County Clerk**

4. bears the seal/stamp of the county of **Westchester**

Certified

5. At Albany, New York 6. the 12th day of August 2010

7. by Secretary of State, State of New York

8. No. A-118100C

9. Seal/Stamp 10. Signature

STATE OF NEW YORK ★ DEPARTMENT OF STATE ★ EXCELSIOR

Lorraine Cortés-Vázquez

Lorraine Cortés-Vázquez
Secretary of State

SEP 2010

04135595.RSL (REV: 07/16/10)

10

Clarke, Modet & Cº
COLOMBIA

COLOMBIA

Carrera 11 Nº 86-53 Piso 6 Bogotá Colombia Tel: (57 1) 6181088 Fax: (57 1) 6350824-Email: info@clarkemodet.com.co

PODER

Yo (nosotros), abajo firmante(s)

R. Scott Meece

en mi (nuestro) carácter de representante(s) legales de **BAYER HEALTH CARE LLC.**

una sociedad organizada y existente de acuerdo con las leyes de el estado de Delaware

y en actual cumplimiento de su objeto social, con domicilio en **555 Whire Plains Road, Tarrytown, New York 10591, Estados Unidos de América.**

por el presente instrumento confiero (conferimos) poder especial a favor de DILIA MARIA RODRIGUEZ D'ALEMAN, con Cédula de Ciudadanía No. 41.654.882 de Bogotá, y tp. 20824 y CLAUDIA LUCIA CARO RAMIREZ, con Cédula de Ciudadanía No. 40.017.374 de Tunja, y tp. 36448, con domicilio en Bogotá, Colombia, para que actuando en su orden en nombre del (de la) otorgante le (la) representen ante cualquier entidad, autoridad y/o persona, especialmente ante las del orden Administrativo, Contencioso Administrativo, Judicial, Tribunales de Arbitramento y/o cualquier otro en lo referente a los siguientes asuntos:

1) Solicitar, tramitar, obtener y/o registrar cualquiera de las modalidades de Propiedad Industrial, tales como: patentes de invención, modelos de utilidad; diseños industriales, variedades vegetales; marcas, lemas, nombres y enseñas comerciales y denominaciones de origen; así como sus renovaciones, prórrogas, transferencias, cambios de nombre y/o domicilio, contratos y licencias.
2) Solicitar, tramitar, obtener y/o registrar derechos de autor, en cualquiera de sus presentaciones así como la protección de secretos industriales y know-how.
3) Solicitar, tramitar, obtener y/o registrar registros sanitarios, permisos y/o licencias de funcionamiento; así como sus renovaciones o prórrogas, transferencias, cambios de nombre y/o domicilio, contratos y licencias.
4) Ejercer acciones de oposición, observación, reclamos, reconsideración, reposición, apelación, cancelación administrativa o judicial, nulidad, protección al consumidor, concesión de licencias, protección de secretos industriales y demás acciones y recursos relacionados con derechos derivados de los asuntos arriba indicados y en contra de la competencia desleal, acciones derivadas de la obtención o explotación de licencias, acciones de indemnización de perjuicios. También podrá(n) intervenir en juicios civiles, comerciales, penales, contencioso-administrativos, tutelas y de policía; en acciones o juicios promovidos por el (la) mandante o en contra el (ella) .
5) Registrar nombres de dominio ante la entidad competente.
6) En el ejercicio de este mandato los mandatarios arriba mencionados quedan facultados para: conciliar, cancelar, transigir, comprometer en árbitros, desistir, recibir y tomar posesión de la cosa objeto de litigio y renunciar o desistir a derechos concedidos o en curso de concesión, admitir los hechos del proceso.
7) Ratificar o no la agencia oficiosa.
8) Así mismo faculto (facultamos) a los mencionados apoderados para recibir notificaciones y designar apoderados judiciales o extrajudiciales, sustituir el presente poder y revocar las sustituciones que hicieren.

POWER OF ATTORNEY

I (we), the undersigned

R. Scott Meece

legal representative(s) of **BAYER HEALTH CARE LLC.**


an organization existing under the laws of the State of Delaware, United States of America

and in present execution of its business activity, domiciled **555 White Plains Road, Tarrytown, New York 10591, United States of America.**

do hereby grant POWER OF ATTORNEY to DILIA MARIA RODRIGUEZ D'ALEMAN, identification card No. 41.654.882 of Bogotá, and tp. 20824 and CLAUDIA LUCIA CARO RAMIREZ, tp. 36448, identification card No. 40.017.374 of Tunja, residing in Bogotá, Colombia, to act in the order of their appointment in behalf of grantor before any entity, authority and/or natural or juridical person, specially before those Administrative, Administrative-Contentious, Judicial, arbitration courts, and/or any other, in all matters concerning the following:

Patent Application No. 00001451, Patent No. 28604, titled "ω-carboxyarl substituted diphenyl ureas as raf kinase inhibitors,"

1) To apply, process, obtain and/or register any of the modalities of Industrial Property, such as: Patents of Invention, Utility Models; Designs, plant varieties; Marks, Slogans, Trade Names and emblems and appellations of Origin; as well as their renewals, assignments, changes of name and/or domicile, agreements and licenses.
2) To apply, process, obtain and/or register copyrights of any kind as well as protection of industrial secrets or know-how.
3) To apply, process, obtain and/or register sanitary registrations, operating authorizations and/or licenses; as well as their renewals or assignments, changes of name and/or domicile, agreements and licenses.
4) To bring actions of opposition, observations, claims, reconsideration, appeal or legal remedies, cancellations, nullity, protection to the consumer, granting of licenses, protection of trade secrets and other actions related with rights derived from the above- mentioned matters and against the unfair competition, actions resulting from the obtaining or exploitation of licenses, recovering damages actions. They can also intervene or participate in Civil, Commercial, Criminal or Contentious-Administrative Trials; the actions for writ mandamus, police actions; in actions, lawsuits or litigations instituted by the grantor or against him.
5) To register domain names before the competent entity.
6) To the effect of this mandate the above-named proxy are empowered to: conciliate, cancel, settle, submit to arbitration, withdraw and to receive and take possession of the litigation related objet and waive or renounce the rights granted or in process of granting, admit the facts of the case.
7) To ratify or not the officious agency.
8) I (we) hereby appoint the afore mentioned attorneys with powers to receive notifications and to designate judicial and extrajudicial attorneys, substitute this Power of Attorney and to revoke such sustitutions.



Dado y firmado en
a los días de

Firma / signatura

R. Scott Meece

Granted and signed at Tarrytown, New York, United States of America
on this 25th day of July of
2010

Signature: R Scott Meece
Name: R. Scott Meece
Title: General Counsel, Sr. V. P., Secretary and
Authorized Officer



PODER / POWER OF ATTORNEY

CERTIFICADO NOTARIAL

(Cuando el solicitante es SOCIEDAD)

(Poderes otorgados en: El Salvador, Estados Unidos, México y Venezuela)

En el día de hoy se presentó ante mi el Señor (a) _____ a quien conozco personalmente y que firma éste documento en representación de la compañía denominada_____, y certifico que he revisado los documentos que legalmente prueban lo siguiente:

1. Que la compañía fue constituida y existe de acuerdo con las leyes de: _____
2. Que el domicilio de esta compañía es: _____
3. Que la compañía desarrolla actualmente su objeto social.
4. Que el Señor(a)_____ está autorizado para otorgar este poder

_____
Notario Público

NOTA: A continuación de lo anterior, el Cónsul de Colombia debe autenticar la firma del Notario Público.

Para todos los demás países el Señor Cónsul de Colombia o ante quien se otorgue, debe expedir una certificación dejando constancia 1) de la existencia legal de la sociedad, 2) de que esta ejerce actualmente su objeto social, y 3) de que la persona o personas que otorgan el poder están facultadas para hacerlo, dejando constancia así mismo de que tuvo a la vista las pruebas que acrediten tales circunstancias.

LEGALIZACIÓN POR EL CONSUL DE COLOMBIA O POR APOSTILLA

NOTARIAL CERTIFICATE

(When the applicant is a CORPORATION)

(Powers of attorney granted in: El Salvador, Mexico, U.S.A. and Venezuela)

On this 28 day of July, 2010, I,

Paula A. Harney, certify that R. Scott Meece personally appeared before me, proved through satisfactory evidence that he is the person whose name is signed on the preceding or attached instrument, and acknowledged to me that he executed the same in his authorized capacity as General Counsel and Secretary of Bayer HealthCare LLC domiciled at 555 White Plains Road, Tarrytown, New York, 10591, UNITED STATES and which is a corporation in good standing constituted and existing in accordance with the laws of Delaware, that officers of Bayer HealthCare LLC have power to sign documents on behalf of Bayer HealthCare LLC in accordance with resolutions adopted at the meeting of the Board of Directors held on April 16, 2003, and that by his signature on the instrument he, or the entity on behalf of which he acted, executed the instrument.

United States of America)
State of New York) SS
County of Westchester)

Paula A. Harney Notary Public
Signature

PAULA A. HARNEY
Notary Public - State of New York
No. 4899023
Qualified in Westchester County
My Commission Expires July 6, 20 11

NOTA: Then the Colombian Consul must legalize the signature of the Notary Public.

For all other countries the Colombian Consul or before who it is granted must issue a certification stating 1) the legal existence of the corporation, 2) that the corporate purposes are actually being accomplished , 3) that the person or persons who grant this Power of Attorney are empowered to do it. The Consul will certify also that the documents evidencing those circumstances were exhibited to him.

LEGALIZATION BY THE COLOMBIAN CONSUL OR BY APOSTILLE.

ELABORADO:	REVISADO:	APROBADO:	CODIGO
DILIA RODRÍGUEZ D´ALEMAN			
	JULIANA ESCOBAR	DILIA RODRÍGUEZ D´ALEMAN	

Consulado de Colombia del Circulo de Bogotá D.C. hace constar que ésta COPIA concide con su Original que se le presentó
1 SEP 2010
BOGOTA D.C.

917

JIMENA ESCOBAR URIBE
Traductor e Intérprete Oficial
Resolución No. 0369 Min. Justicia 1995

Traducción oficial hecha por Jimena Escobar Uribe, traductora e intérprete oficial según resolución No. 0369 de 1995 del Ministerio de Justicia, del documento legalizado mediante la **APOSTILLA** No. **236390** de 20 de agosto de 2010 expedida en Estados Unidos de América (Washington D.C.) correspondiente a un certificado correspondiente la sociedad **BAYER HEALTHCARE LLC.**

Delaware Página 1

El Primer Estado

Yo, Jeffrey W. Bullock, Secretario de Estado del Estado de Delaware, por medio del presente certifico que "BAYER HEALTHCARE LLC" está debidamente constituida bajo las leyes del Estado de Delaware y está en vigencia y tiene existencia legal corporativa en cuanto muestran los registros de esta oficina, en este día diecinueve de mayo de 2010.

Firmado: Jeffrey W. Bullock, Secretario de Estado
Autenticación: 8003494
Fecha: 05-19-10
Sello de la Oficina del Secretario, Delaware

Yo certifico que esta es una copia verdadera del original.
Firmado por firma ilegible

Sello: Suscrito y juramentado ante mí en mi presencia en este día 20 de agosto de 2010, un notario público en y para el Distrito de Columbia.
Firmado: Firma ilegible
Mi comisión termina el 31 de agosto de 2013

Cámara de Comercio de Bogotá
Oficina del Circulo de Notarías
Bogotá, D.C.
FOTOCOPIA
Se hace constar que ésta coincide con su Original
que se ha tenido a la vista
1 SEP 2010

74

JIMENA ESCOBAR URIBE
Traductor e Intérprete Oficial
Decreto No 0369 Min. Justicia 1995

****

APOSTILLA

(Convención de la Haya de 5 de octubre de 1961)

1. País: Distrito de Columbia, Estados Unidos de América
2. Este documento público ha sido firmado por JANET KING
3. Actuando en su calidad de notario público en y para el Distrito de Columbia
4. Lleva el sello/estampilla de Janet King, notario público en y para el Distrito de Columbia

CERTIFICADO

5. En Washington, D.C.
6. El 23 de marzo de 2010
7. Por el Secretario del Distrito de Columbia
8. NO. 236390
9. Sello/Estampilla: Sello del Distrito de Columbia
10. Firma: Firmado por Stephanie D. Scott

Como Notaria Única del Círculo de Bogotá, D.C., hago constar que ésta FOTOCOPIA concuerda con su Original que he tenido a la vista.
8 SEP 2010

919

Apostille

(Convention de La Haye du 5 octobre 1961)

1. *District of Columbia*
   United States of America
2. This public document has been signed by VINCENT L. BADDERS
3. acting in the capacity of NOTARY PUBLIC IN AND FOR THE DISTRICT OF COLUMBIA
4. bears the seal/stamp of VINCENT L. BADDERS, NOTARY PUBLIC IN AND FOR THE DISTRICT OF COLUMBIA

CERTIFIED

5. at Washington, D.C.
6. the 20th day of AUGUST 2010
7. by *Secretary of the District of Columbia*
8. No 236390

10. Signature

Stephanie D. Scott

86 – PO138

16

920

Delaware

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "BAYER HEALTHCARE LLC" IS DULY FORMED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE NINETEENTH DAY OF MAY, A.D. 2010.

I certify this is a true copy of the original

Subscribed and sworn to before me, in my presence, this 20 day of August 2010, a Notary Public in and for the District of Columbia

My commission expires August 31, 2013

SECRETARY'S OFFICE 1793 DELAWARE 1855

3 SEP 2010

Jeffrey W. Bullock, Secretary of State

3536270 8300

100533990

AUTHENTICATION: 8003494

DATE: 05-19-10

You may verify this certificate online at corp.delaware.gov/authver.shtml

17

2

P291 921

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: *United States of America*

This public document

2. has been signed by P. Swain

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of Patent and Trademark Office

Certified

5. at Washington, D.C.

6. the seventeenth of May, 2010


7. by *Assistant Authentication Officer, United States Department of State*

8. No. 10025169-14

9. Seal/Stamp:

10. Signature:

Sonya N. Johnson



18

1

922

A 7234279

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

April 09, 2010

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON JULY 27, 2009.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office

P. SWAIN
Certifying Officer

SEP 2010

19
2

JUL 27 2009
PATENT & TRADEMARK OFFICE

Form PTO-1595 (Rev. 03-09)
OMB No. 0651-0027 (exp. 03/31/2009)

07-30-2009

PARTMENT OF COMMERCE
ates Patent and Trademark Office

RECORD

P 103569089

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, Connecticut 06516

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies)

Name: Bayer HealthCare LLC
Internal Address:
Street Address: 555 White Plains Road
City: Tarrytown
State: New York
Country: USA Zip: 10591

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) 12/19/07 & 12/21/07

☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)
See attached sheets

B. Patent No.(s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Barbara A. Shimei
Internal Address: Director of Patents & Licensing, 3rd Floor
Street Address: 555 White Plains Road
City: Tarrytown
State: New York Zip: 10591
Phone Number: 914-333-6945
Fax Number: 914-333-6831
Email Address: Barbara.shimei.b@bayer.com

6. Total number of applications and patents involved: 88

7. Total fee (37 CFR 1.21(h) & 3.41) $ 3,520.00

☒ Authorized to be charged to deposit account
☐ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

Deposit Account Number
Authorized User Name William F. Gray

07/29/2009 DBYRNE 00000024 133372 PCT/US02/0
01 FC:8021 3520.00 CR

9. Signature:

William F. Gray
Signature

7/24/09
Date

William F. Gray
Name of Person Signing

Total number of pages including cover sheet, attachments, and any documents: 20

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

13 SEP 2010
NOTARIO

924


	Country	App. No.
1	PCT	PCT/US02/03361
2	PCT	PCT/US03/04110
3	PCT	PCT/US04/015655
4	PCT	PCT/US05/030542
5	PCT	PCT/US05/33095
6	PCT	PCT/US06/44117
7	PCT	PCT/US06/44238
8	PCT	PCT/US07/07965
9	PCT	PCT/US07/12477
10	US	09/083,396
11	US	09/083,399
12	US	09/257,265
13	US	09/257,266
14	US	09/285,521
15	US	09/285,522
16	US	09/303,621
17	US	09/425,228
18	US	09/425,229
19	US	09/458,014
20	US	09/458,015
21	US	09/458,548
22	US	09/472,232
23	US	09/479,125
24	US	09/640,780
25	US	09/722,418
26	US	09/755,060
27	US	09/758,548
28	US	09/773,604
29	US	09/773,658
30	US	09/773,659
31	US	09/773,672
32	US	09/773,675
33	US	09/776,935
34	US	09/776,936
35	US	09/777,920
36	US	09/778,039
37	US	09/838,286
38	US	09/889,227
39	US	09/907,970
40	US	09/947,761
41	US	09/948,915
42	US	09/993,647
43	US	10/042,203

3 SEP 2010

2
4

926

44	US	10/042,226
45	US	10/060,396
46	US	10/071,248
47	US	10/086,417
48	US	10/125,369
49	US	10/283,248
50	US	10/308,187
51	US	10/361,844
52	US	10/361,850
53	US	10/361,858
54	US	10/361,859
55	US	10/571,100
56	US	10/576,733
57	US	10/581,125
58	US	10/659,639
59	US	10/675,406
60	US	10/788,029
61	US	10/788,405
62	US	10/788,426
63	US	10/789,446
64	US	10/848,567
65	US	10/895,985
66	US	11/149,332
67	US	11/158,048
68	US	11/212,109
69	US	11/212,907
70	US	11/480,360
71	US	11/579,093
72	US	11/589,295
73	US	11/598,824
74	US	11/754,082
75	US	11/768,104
76	US	11/768,112
77	US	11/768,533
78	US	11/775,457
79	US	11/845,595
80	US	11/845,597
81	US	11/932,397
82	US	11/932,548
83	US	11/932,626
84	US	11/956,111
85	US	60/489,102
86	US	60/536,734
87	US	60/885,728
88	US	60/885,731



22

5

ASSIGNMENT

ASSIGNOR, **Bayer Pharmaceuticals Corporation**, 400 Morgan Lane, West Haven, Connecticut, 06516, U.S.A., a corporation organized under the laws of the State of Delaware, United States of America, effective as of August 1, 2007,

sold, assigned, and transferred its entire right, title and interest in and to the patents and patent applications listed in the attached Schedule, and in each case, all patents granted thereon or claiming priority thereto or claiming common priority therewith, including all substitutions, divisions, continuations, continuations-in-part, reissues, reexaminations or extensions of any of such patent applications or patents, and respective supplementary protection certificates, by an agreement executed on December 19, 2007 and December 21, 2007 and effective as of August 1, 2007, to

ASSIGNEE, **Bayer HealthCare LLC**, located at 555 White Plains Road, Tarrytown, New York, 10591, a corporation organized under the laws of the State of Delaware, United States of America, which accepted the same effective as of August 1, 2007.

IN WITNESS WHEREOF, I have hereunto respectively set my hand on the date shown below:

Name of Officer: Keith Abrams
Name of Company: Bayer Pharmaceuticals Corporation

Date: July 1, 2009 **Signature:** Keith R Abrams
Authorized Representative (Assistant Secretary)

Notarization:
United States of America
Commonwealth of Pennsylvania
County of Allegheny

Signed before me this 1st day of July, 2009 by Keith R. Abrams.

Barbara Stemmler
Notary Public

COMMONWEALTH OF PENNSYLVANIA
Notarial Seal
Barbara Stemmler, Notary Public
Robinson Twp., Allegheny County
My Commission Expires Aug. 27, 2012
Member, Pennsylvania Association of Notaries

Accepted by:

Name of Officer: R. Scott Meece
Name of Company: Bayer HealthCare LLC

Date: July 10, 2009 **Signature:** R Scott Meece
Authorized Representative (Secretary)

Notarization:
State of New York
County of Westchester

On this 10th day of July, 2009, before me personally came R. Scott Meece, to me known and known to me to be the person who executed the foregoing instrument.


Paula A. Harney

PAULA A. HARNEY
Notary Public - State of New York
No. 4899023
Qualified in Westchester County
My Commission Expires July 6, 20 11


STM 267417.1

Schedule of Transferred Patents and Patent Applications


Country	App. No.
AE	P171/07
AR	P 00 01 00153
AR	P 050103568
AR	P0401 02614
AR	P040100640
AU	19054/99
AU	19055/99
AU	19399/99
AU	19970/99
AU	19971/99
AU	2003204708
AU	2003213527
AU	2004200566
AU	2004200722
AU	2004217977
AU	2004259760
AU	2005279996
AU	2006/201959
AU	21989/99
AU	25016/00
AU	27250/00
BG	02786842.1
BG	104597
BG	104598
BG	104599
BG	105763
BG	109688
BO	SP-200012
BR	P10407897-7
BR	P10514715.8
BR	PI 0007487-0
BR	PI 0412219-4
BR	PI 9814361-1
BR	PI 9814374-3
BR	PI 9814375-1
BS	1213
BS	1740
BS	1761
CA	2,290,520
CA	2,291,065
CA	2,315,646
CA	2,315,647
CA	2,315,713
CA	2,315,715
CA	2,315,717



Country	App. No.
CA	2,315,720
CA	2,359,244
CA	2,468,463
CA	2,475,703
CA	2,499,852
CA	2,516,624
CA	2,516,627
CA	2,517,361
CA	2,532,865
CA	2,544,855
CA	2,548,394
CA	2,549,558
CA	2359510
CA	2443950
CA	2443952
CA	2475818
CA	2516931
CA	2526617
CA	2526636
CA	2578438
CA	2578442
CL	0384-2004
CL	1834-2004
CL	2173-2005
CL	71-2000
CN	00802685.8
CN	03803705.X
CN	200410028655.6
CN	200480011547.6
CN	200480021091.1
CN	200510089504.6
CN	200580022290.9
CN	200580036952.8
CN	200580037151.3
CN	98812503.X
CN	98812504.8
CN	98813623.6
CO	00001451
CO	06-5884
CO	07-28925
CR	8212
CR	8980
CU	168/2001
CU	2000-0152
CU	2000-0153
CU	2000-0154
CU	2004.118




Country	App. No.
CU	2006-0013
CU	2007-0049
CZ	PV 2000-2349
CZ	PV 2000-2350
CZ	PV 2000-2351
CZ	PV 2001-2489
CZ	PV 2006-706
DO	2005-000169
DO	P-2004/01/03/01
DO	P-2004/21/03/07/02
DZ	0006/2000
DZ	040180
DZ	060082
DZ	070206
EA	200600317
EA	200700501
EC	04-5178
EC	07-5178
EC	SP-06-6302
EC	SP-07-7299
EC	SP-2000-3318
EE	P200100368
EG	216/2007
EG	39/2000
EG	PCT/58/2006
EPO	00903239.2
EPO	00905597.1
EPO	02725709.6
EPO	02725710.4
EPO	02786842.1
EPO	03707846.6
EPO	03707848.2
EPO	03781302.9
EPO	04716136.9
EPO	04716142.7
EPO	04716144.3
EPO	04716166.6
EPO	04786091.1
EPO	04814106.3
EPO	04818346.1
EPO	05007027.5
EPO	05012144.1
EPO	05028442.1
EPO	0578149.4
EPO	05791660.3
EPO	05792486.2
EPO	06023696.5




930

Country	App. No.
EPO	2704353.8
EPO	3026051.7
EPO	4752642.1
EPO	4776037.6
EPO	98 923 601.3
EPO	98923600.5
EPO	98963809.3
EPO	98963810.1
EPO	98964221.0
EPO	98964708.6
EPO	98964709.4
EPO	98965981.8
EPO/AL	00903239.2
EPO/AL	02786842.1
EPO/AL	05028442.1
EPO/AL	98963810.1
EPO/AL	98964221.0
EPO/AL	98964708.6
EPO/AL	98965981.8
EPO/AT	00903239.2
EPO/AT	02725710.4
EPO/AT	02786842.1
EPO/AT	04752642.1
EPO/AT	04786091.1
EPO/AT	05028442.1
EPO/AT	4776037.6
EPO/AT	98923600.5
EPO/AT	98963809.3
EPO/AT	98963810.1
EPO/AT	98964221.0
EPO/AT	98964708.6
EPO/AT	98965981.8
EPO/BE	00903239.2
EPO/BE	02725710.4
EPO/BE	02786842.1
EPO/BE	04752642.1
EPO/BE	04786091.1
EPO/BE	05028442.1
EPO/BE	4776037.6
EPO/BE	98923600.5
EPO/BE	98963809.3
EPO/BE	98963810.1
EPO/BE	98964221.0
EPO/BE	98964708.6
EPO/BE	98965981.8
EPO/BG	04786091.1
EPO/CH	00903239.2




27
10


Country	App. No.
EPO/CH	02725710.4
EPO/CH	02786842.1
EPO/CH	04786091.1
EPO/CH	05028442.1
EPO/CH	4776037.6
EPO/CH	98923600.5
EPO/CH	98963809.3
EPO/CH	98963810.1
EPO/CH	98964221.0
EPO/CH	98964708.6
EPO/CH	98965981.8
EPO/CY	00903239.2
EPO/CY	0275710.4
EPO/CY	02796942.1
EPO/CY	04786091.1
EPO/CY	05028442.1
EPO/CY	98923600.5
EPO/CY	98963809.3
EPO/CY	98963810.1
EPO/CY	98964221.0
EPO/CY	98964708.6
EPO/CY	98965981.8
EPO/CZ	02786842.1
EPO/CZ	04786091.1
EPO/DE	00903239.2
EPO/DE	02725710.4
EPO/DE	02786842.1
EPO/DE	04786091.1
EPO/DE	05028442.1
EPO/DE	4776037.6
EPO/DE	69831013.6-08
EPO/DE	98923600.5
EPO/DE	98963809.3
EPO/DE	98963810.1
EPO/DE	98964221.0
EPO/DE	9896708.6
EPO/DK	00903239.2
EPO/DK	02725710.4
EPO/DK	02786842.1
EPO/DK	04786091.1
EPO/DK	05028442.1
EPO/DK	4776037.6
EPO/DK	98923600.5
EPO/DK	98963809.3
EPO/DK	98963810.1
EPO/DK	98964221.0
EPO/DK	98964708.6




Country	App. No.
EPO/DK	98965981.8
EPO/EE	02786842.1
EPO/EE	04786091.1
EPO/ES	00903239.2
EPO/ES	02725710.4
EPO/ES	02786842.1
EPO/ES	04786091.1
EPO/ES	05028442.1
EPO/ES	4776037.6
EPO/ES	98923600.5
EPO/ES	98963809.3
EPO/ES	98963810.1
EPO/ES	98964221.0
EPO/ES	98964708.6
EPO/ES	98965981.8
EPO/FI	00903239.2
EPO/FI	02725710.4
EPO/FI	02786842.1
EPO/FI	04786091.1
EPO/FI	05028442.1
EPO/FI	98923600.5
EPO/FI	98963809.3
EPO/FI	98963810.1
EPO/FI	98964221.0
EPO/FI	98964708.6
EPO/FI	98965981.8
EPO/FR	00903239.2
EPO/FR	02725710.4
EPO/FR	02786842.1
EPO/FR	04786091.1
EPO/FR	05028442.1
EPO/FR	4776037.6
EPO/FR	98923600.5
EPO/FR	98963809.3
EPO/FR	98963810.1
EPO/FR	98964221.0
EPO/FR	98964708.6
EPO/FR	98965981.8
EPO/GB	02725710.4
EPO/GB	02786842.1
EPO/GB	04786091.1
EPO/GB	05028442.1
EPO/GB	0903239.2
EPO/GB	4776037.6
EPO/GB	98923600.5
EPO/GB	98963809.3
EPO/GB	98963810.1



Country	App. No.
EPO/GB	98964221.0
EPO/GB	98964708.6
EPO/GB	98965981.8
EPO/GR	00903229.2
EPO/GR	02725710.4
EPO/GR	02786842.1
EPO/GR	04786091.1
EPO/GR	05028442.1
EPO/GR	98923600.5
EPO/GR	98963809.3
EPO/GR	98963810.1
EPO/GR	98964221.0
EPO/GR	98964708.6
EPO/GR	98965981.8
EPO/HU	04786091.1
EPO/IE	00903229.2
EPO/IE	02725710.4
EPO/IE	02786842.1
EPO/IE	04786091.1
EPO/IE	05028442.1
EPO/IE	98923600.5
EPO/IE	98963809.3
EPO/IE	98963810.1
EPO/IE	98964221.0
EPO/IE	98964708.6
EPO/IE	98965981.8
EPO/IT	00903239.2
EPO/IT	02725710.4
EPO/IT	02786842.1
EPO/IT	04786091.1
EPO/IT	05028442.1
EPO/IT	4776037.6
EPO/IT	98923600.5
EPO/IT	98963809.3
EPO/IT	98963810.1
EPO/IT	98964221.0
EPO/IT	98964708.6
EPO/IT	98965981.8
EPO/KR	7002656/2007
EPO/LI	04786091.1
EPO/LT	00903239.2
EPO/LT	02786842.1
EPO/LT	05028442.1
EPO/LT	98963810.1
EPO/LT	98964221.0
EPO/LT	98964708.6
EPO/LT	98965981.8




Country	App. No.
EPO/LU	00903239.2
EPO/LU	02725710.4
EPO/LU	027986842.1
EPO/LU	04786091.1
EPO/LU	05028442.1
EPO/LU	9863810.1
EPO/LU	98923600.5
EPO/LU	98963809.3
EPO/LU	98964221.0
EPO/LU	98964708.6
EPO/LU	98965981.8
EPO/LV	00903239.2
EPO/LV	02786842.1
EPO/LV	05028442.1
EPO/LV	98963810.1
EPO/LV	98964221.0
EPO/LV	98964708.6
EPO/LV	98965981.8
EPO/MC	00903239.2
EPO/MC	02725710.4
EPO/MC	02786842.1
EPO/MC	04786091.1
EPO/MC	05028442.1
EPO/MC	98923600.5
EPO/MC	98936810.1
EPO/MC	98963809.3
EPO/MC	98964221.0
EPO/MC	98964708.6
EPO/MC	98965981.8
EPO/MK	00903239.2
EPO/MK	02786842.1
EPO/MK	05028442.1
EPO/MK	98936810.1
EPO/MK	98964221.0
EPO/MK	98964708.6
EPO/MK	98965981.8
EPO/NL	00903239.2
EPO/NL	02725710.4
EPO/NL	02786842.1
EPO/NL	04786091.1
EPO/NL	05028442.1
EPO/NL	4776037.6
EPO/NL	98923600.5
EPO/NL	98963809.3
EPO/NL	98963810.1
EPO/NL	98964221.0
EPO/NL	98964708.6



935

Country	App. No.
EPO/NL	98965981.8
EPO/PL	04786091.1
EPO/PL	4776037.6
EPO/PT	00903239.2
EPO/PT	02725710.4
EPO/PT	02786842.1
EPO/PT	04786091.1
EPO/PT	05028442.1
EPO/PT	4776037.6
EPO/PT	98923600.5
EPO/PT	98936810.1
EPO/PT	98964221.0
EPO/PT	98964708.6
EPO/PT	98965981.8
EPO/RO	00903229.2
EPO/RO	02786842.1
EPO/RO	04786091.1
EPO/RO	05028442.1
EPO/RO	98936810.1
EPO/RO	98964221.0
EPO/RO	98964708.6
EPO/RO	98965981.8
EPO/SE	00903229.2
EPO/SE	02725710.4
EPO/SE	02786842.1
EPO/SE	04786091.1
EPO/SE	05028442.1
EPO/SE	4776037.6
EPO/SE	98923600.5
EPO/SE	98936810.1
EPO/SE	989638093.
EPO/SE	98964221.0
EPO/SE	98964708.6
EPO/SE	98965981.8
EPO/SI	02786842.1
EPO/SI	04786091.1
EPO/SI	05028442.1
EPO/SI	98936810.1
EPO/SI	98964221.0
EPO/SK	02786842.1
EPO/SK	04786091.1
EPO/SK	PP 5096-2006
EPO/SK	PV0988-2001
EPO/SL	00903239.2
EPO/SL	05028442.1
EPO/SL	98964708.6
EPO/SL	98965981.8




PATENT
REEL: 023031 FRAME: 0975


32

15

Country	App. No.
EPO/TR	02725710.4
EPO/TR	02786842.1
EPO/TR	04786091.1
EPO/TR	4776037.6
GT	2005-0230
GT	PI2000/0002
GT	PI2000/002 A
GT	PI-2004-0031
GT	PI-2004-0140
HK	00105455.7
HK	00105456.6
HK	00107643
HK	00107684.6
HK	01100659.1
HK	01102469.7
HK	02104153.3
HK	02106872.8
HK	04105146.8
HK	04105147.7
HK	05111827.1
HK	06106288.2
HK	06107837.6
HK	07100236.7
HK	1102470.4
HK	1102768.8
HN	PI/DE2004254
HN	PI/US2000/07
HN	PI/USA2004/71
HN	PI-US-484-2005
HR	P20010580A
HR	P20060073A
HU	P0004426
HU	P0004437
HU	P0101704
HU	P0300866
HU	P0600871
ID	W-00200101747
ID	W-002006/00196
ID	W-00200700651
ID	W-00200802549
ID	W-20001415
ID	W-20001417
ID	W-20001429
IL	136690
IL	136737
IL	136738
IL	136767




Country	App. No.
IL	136768
IL	136773
IL	144030
IL	144144
IL	170201
IL	170235
IL	170503
IL	173256
IL	181590
IN	1101/MUMNP/2003
IN	1420/DELNP/2004
IN	1633/MUMNP/2007
IN	1788/DELNP/2007
IN	2000, 00151
IN	2000, 00153/MUM
IN	200100799
IN	3802/DELNP/2005
IN	402/DELNP/2006
IN	811/MUMNP/2003
IN	IN/PCT/2000,
IN	IP 960/MUMNP/2003
IN	IP990/MUMNP/2003
IR	37810035
JM	18/1/3974
JM	18/1/4318
JM	18/1/4339
JM	18/1/4387
JO	137/5
JO	22/2006
KP	00-1105
KP	00-1107
KP	00-1108
KR	10-2005-7015997
KR	10-2006-7001558
KR	10-2007-7006801
KR	7006929/2000
KR	7007014/2000
KR	7007015/2000
KR	7008847/2001
KW	2PA/2000
LB	6124
MA	28799
MA	29767
MA (CASABLANCA	26289
MA (TANGIER ZONE)	1836
MA (TANGIER ZONE)	2077
MX	006226



938


Country	App. No.
MX	006227
MX	006228
MX	006233
MX	2003/009648
MX	2003/009649
MX	2005/009102
MX	2005/009103
MX	2005/009104
MX	MX/a/002398
MX	MX/a/2007/002397
MX	PA/a/006232
MX	PA/a/2000/006231
MX	PA/A/2001/007118
MX	PA/A/2001/007120
MX	PA/A/2004/005137
MX	PA/a/2004/007830
MX	PA/A/2004/007832
MX	PA/a/2005/009067
MX	PA/a/2005/012486
MX	PA/a/2005/012491
MX	PA/a/2006/000860
MX	PA/a/2006012394
MY	PI 20000102
MY	PI 20042941
MY	PI20040669
MY	PI20054000
NG	03/2000
NG	07/2006
NG	103/07
NI	2004-0141
NI	2006-00016
NI	2007-000064
NI	84897-1
NO	2000-3230
NO	2000-3231
NO	2000-3232
NO	2001 3463
NO	2005 5863
NO	20060870
NO	20071584
NZ	505843
NZ	505844
NZ	505845
NZ	513079
NZ	534209
NZ	544920
NZ	553557



PATENT
REEL: 023031 FRAME: 0978


35

Country	App. No.
NZ	556598
OM	24/2007
PA	99/084897
PCT	PCT/US02/03361
PCT	PCT/US03/04110
PCT	PCT/US04/015655
PCT	PCT/US05/030542
PCT	PCT/US05/33095
PCT	PCT/US06/44117
PCT	PCT/US06/44238
PCT	PCT/US07/07965
PCT	PCT/US07/12477
PE	000210-2004
PE	000709-2004
PE	000984-2005 OIN
PE	07289
PH	1-2000-00073
PH	1-2006-500171
PH	1-2007-0500481
PK	0148/04
PK	0780/05
PK	28/2000
PK	533/2004
PL	P-341356
PL	P-342078
PL	P-343083
PL	P-360085
PL	P-382110
PY	6/2000
RU	2000120162
RU	2000120165
RU	2000120184
RU	2001122818
RU	2004120785
SA	3567
SG	200003516-2
SG	200003518-8
SG	200003520-4
SG	200104237-3
SG	200600441.0
SG	200701373-3
SK	PV 0961-2000
SK	PV 0962-2000
SK	PV 0963-2000
SV	012000000004
SV	2536/2006
SV	E-2412-04



940

Country	App. No.
SV	E-2776-04
SV	E-3802-2005
TH	055106
TH	089071
TH	092472
TH	103605
TN	06020
TN	07.076
TN	SN.00.010
TR	2000/02616
TR	2000/02617
TR	2000/02618
TR	2001/00874
TR	2001/00917
TR	2001/00918
TR	2001/02020
TT	TT/A/2001/00124
TT	TT/A/2007/0048
TW	093105295
TW	093122197
TW	094129395
TW	89100575
UA	2000074352
UA	2000074353
UA	2000074354
UA	2001075426
UA	A 2006 00766
UA	a2007 03203
US	09/083,396
US	09/083,399
US	09/257,265
US	09/257,266
US	09/285,521
US	09/285,522
US	09/303,621
US	09/425,228
US	09/425,229
US	09/458,014
US	09/458,015
US	09/458,548
US	09/472,232
US	09/479,125
US	09/640,780
US	09/722,418
US	09/755,060
US	09/758,548
US	09/773,604




PATENT
REEL: 023031 FRAME: 0980

37

941


Country	App. No.
US	09/773,658
US	09/773,659
US	09/773,672
US	09/773,675
US	09/776,935
US	09/776,936
US	09/777,920
US	09/778,039
US	09/838,286
US	09/889,227
US	09/907,970
US	09/947,761
US	09/948,915
US	09/993,647
US	10/042,203
US	10/042,226
US	10/060,396
US	10/071,248
US	10/086,417
US	10/125,369
US	10/283,248
US	10/308,187
US	10/361,844
US	10/361,850
US	10/361,858
US	10/361,859
US	10/571,100
US	10/576,733
US	10/581,125
US	10/659,639
US	10/675,406
US	10/788,029
US	10/788,405
US	10/788,426
US	10/789,446
US	10/848,567
US	10/895,985
US	11/149,332
US	11/158,048
US	11/212,109
US	11/212,907
US	11/480,360
US	11/579,093
US	11/589,295
US	11/598,824
US	11/754,082
US	11/768,104



PATENT
REEL: 023031 FRAME: 0981

38

Country	App. No.
US	11/768,112
US	11/768,533
US	11/775,457
US	11/845,595
US	11/845,597
US	11/932,397
US	11/932,548
US	11/932,626
US	11/956,111
US	60/489,102
US	60/536,734
US	60/885,728
US	60/885,731
UY	26038
UY	28.213
UY	28.428
UY	29.086
VE	107-2000
VE	2004-001256
VE	2004-002064
VE	2005-001750
VN	1-2001-00644
VN	1-2006-00096
VN	1-2007-00652
YU (SERBIA & MONTENEGRO)	P-488/04
YU/Serbia	P-37/2006
YU/Serbia	P-491/2001
ZA	2001/5751
ZA	2004/4225
ZA	2005/06861
ZA	2006/00609
ZA	2007-02392



P 291 943

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: *United States of America*

This public document

2. has been signed by M. K. Carter

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U. S. Patent and Trademark Office

Certified

5. at Washington, D.C.

6. the fourth of August, 2010

7. by *Assistant Authentication Officer, United States Department of State*

8. No. ~~10037~~362-11

9. Seal/Stamp:

10. Signature:

Fernesia T. Crawford

SEP 2010

40

A 1721785

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 02, 2008

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON JUNE 09, 2003.

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office

M. K. CARTER
Certifying Officer

Cotejado con el Original
15 SEP 2010

945

OIPE JUN 09 2003 JC34 PATENT & TRADEMARK OFFICE

06-12-2003

Form PTO-1595

(Rev. 10/02)
OMB No. 0651-0027 (exp. 6/30/2005)

RECORDATION

NT OF COMMERCE
Trademark Office

PA 102471821

To the Honorable Commissioner of Patent and Trademarks: Please record the attached documents or copy thereof.

1. Name of conveying party(ies): 6-9-03
BAYER CORPORATION
100 Bayer Road
Pittsburgh, Pennsylvania 15205

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: BAYER PHARMACEUTICALS CORPORATION

Internal Address: 400 Morgan Lane

Street Address:

City: West Haven State: CT Zip:06516

No additional names(s) or address(es) attached ☐ Yes ☐ No

3. Nature of Conveyance:

☒ Assignment ☐ Merger

☐ Security Agreement ☐ Change of Name

☐ Other

Execution Date: 6/3/03

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is:
A. Patent Application No.(s)
See Attachment FCS

B. Patent No.(s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Address: Arlington Court Plaza I
Suite 1400
2200 Clarendon BLVD.
Arlington, VA 22201

6. Total number of applications and patents involved: 71

7. Total fee (37CFR 3.41) $2840.00

☒ Enclosed
☐ Authorized to be charged to deposit account

8. DEPOSIT ACCOUNT NO. 13-3402

(Attach duplicate copies of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and Signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Richard J. Traverso, Reg. No. 30,595
Names of Person Signing

Signature

June 9, 2003
Date

Attorney Docket No.: BAYER 48X

Total number of pages including cover sheet, attachments, and documents 11

06/11/2003 DBYRNE 00000219 09083299
01 FC:8021 2840.00 DP


3 SEP 2010

42
3

946

ATTACHMENT FCS (FOR COVER SHEET)


TITLE	AP. NO.	FILING DATE
RAF Kinase Inhibitors	09/083,399	5/22/98
Inhibition of RAF Kinase Activity Using Aryl Ureas	09/755,060	1/8/01
RAF Kinase Inhibitors	60/126,420	5/23/97
Inhibition of P38 Kinase Activity by Aryl Ureas	60/098,557	5/22/98
Inhibition of P38 Kinase Activity by Aryl Ureas	08/863,022	5/23/97
Inhibition of P38 Kinase Activity by Aryl Ureas	09/083,396	5/22/97
Inhibition of P 38 Kinase Activity by Aryl Ureas	09/947,761	9/7/01
Inhibition of RAF Kinase Using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas	08/996,344	12/22/97
Inhibition of RAF Kinase Using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas	09/776,936	12/22/98
Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas	08/996,343	12/22/97
Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas	09/640,780	8/18/00
Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas	09/479,125	12/22/98
Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	08/996,181	12/22/97
Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	09/303,621	12/22/98
Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	09/472,232	12/27/98
Inhibition of P 38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas	08/995,749	12/22/97
Inhibition of P 38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas	09/458,015	12/10/99
Inhibition of P 38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas	10/060,396	2/1/02
Inhibition of P 38 Kinase Using Substituted Heterocyclic Ureas	08/995,750	12/22/97
Inhibition of P 38 Kinase Using Substituted Heterocyclic Ureas	09/285,521	12/22/98
Inhibition of P 38 Kinase Using Substituted Heterocyclic Ureas	09/458,014	12/10/99
Inhibition of P 38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	60/135,094	12/22/98
Inhibition of P 38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	08/995,751	12/22/97
Inhibition of P 38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	09/776,935	12/22/98
Inhibition of Raf Kinase Quinolinyl, Isoquinolinyl or Pyridyl Ureas	60/367,376	4/19/01
Inhibition of Raf Kinase Quinolinyl, Isoquinolinyl or Pyridyl Ureas	09/838,285	4/20/01
Inhibition of Raf Kinase Quinolinyl, Isoquinolinyl or Pyridyl Ureas	10/125,369	4/19/02
Heteroaryl Ureas Containing Nitrogen Hetero-Atoms as P 38 Kinase Inhibitors	09/838,286	4/20/01
Inhibition of p38 Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas	60/115,878	1/13/99
Inhibition of p38 Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas	09/257,266	2/25/99
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/425,228	10/22/99




4

43

Inhibition of Raf Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas	60/115,877	1/13/99
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/948,915	9/10/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/889,227	7/12/01
Inhibition of RAF Kinase Using Quinolinyl, Isoquinolinyl and Pyridinyl Ureas	09/758,548	1/12/01
Inhibition of RAF Kinase Using Quinolinyl, Isoquinolinyl and Pyridinyl Ureas	09/777,920	2/7/01
Method and/or Process for Preparing ω-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors	10/071,248	2/11/02
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	09/257,265	1/25/99
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	09/425,229	10/22/99
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	09/778,039	2/7/01
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	10/071,248	2/11/02
Aryl Ureas with Angiogenisis Inhibiting Activity	10/361,858	2/11/03
Aryl Ureas with Angiogenisis Inhibiting Activity	60/354,950	2/11/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	60/367,346	11/28/00
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/722,418	11/27/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/993,647	11/27/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	60/367,379	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	90/758,266	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/758,266	1/11/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	60/367,380	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	09/758,547	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	10/283,248	10/30/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	10/042,203	1/11/02
Rho-Kinase Inhibitors	60/349,987	1/23/02
Rho-Kinase Inhibitors	60/349,986	1/23/02
Rho-Kinase Inhibitors	10/349,177	1/23/03
Rho-Kinase Inhibitors	10/349,176	1/23/03
Rho-Kinase Inhibitors	60/277,974	3/23/01
Rho-Kinase Inhibitors	60/315,338	8/29/01
Rho-Kinase Inhibitors	60/346,628	1/10/02



...inase Inhibitors	10/103,565	3/22/02
Rho-Kinase Inhibitors	10/339,393	1/10/03
Process For Preparing Quinazoline Rho-Kinase Inhibitors And Intermediates Thereof	10/252,369	9/30/02
Aryl Urea Compounds in Combination with Other Cytostatic or Cytotoxic Agents for Treating Human Cancers	60/334,609	12/3/01
Aryl Urea Compounds in Combination with Other Cytostatic or Cytotoxic Agents for Treating Human Cancers	10/308,187	12/3/02
Aryl Ureas as Raf Kinase Inhibitors	60/354,937	2/11/02
Aryl Ureas as Raf Kinase Inhibitors	10/361,859	2/11/03
Aryl Ureas with RAF Kinase and Angiogenesis Inhibiting Activity	60/354,948	2/11/02
Aryl Ureas with RAF Kinase and Angiogenesis Inhibiting Activity	10/361,844	2/11/03
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors	60/354,935	2/11/02
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors	10/361,850	2/11/03



ASSIGNMENT OF INVENTION

In consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of one dollar ($1.00) and for other good and valuable consideration, the receipt of which is hereby acknowledged,

ASSIGNOR: BAYER CORPORATION, 100 Bayer Road, Pittsburgh, Pennsylvania 15205, United States of America, a corporation organized under the laws of the State of Indiana, United States of America,

hereby sell(s), assign(s) and transfer(s) to

ASSIGNEE: BAYER PHARMACEUTICALS CORPORATION, 400 Morgan Lane, West Haven, Connecticut 06516, United States of America, a corporation organized under the laws of the State of Delaware, United States of America, and its successors, assigns and legal representatives,

the entire right, title and interest in and to, including the right to claim priority from, the invention(s) disclosed in the U.S. Applications listed in Attachment A,

and any legal equivalent thereof in a foreign country,

and in and to all Letters Patent and equivalents thereof to be obtained for said invention(s) in all countries by the above application or any continuation, division, renewal, substitute or equivalent thereof, as well as to any reissue, reexamination, patent term restoration, or equivalent thereto.


ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment, and that ASSIGNEE will, upon ASSIGNEE's request, be provided promptly with all pertinent facts and documents relating to said invention(s) and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR, and ASSIGNOR will testify as to the same in any interference, litigation or other proceeding related thereto, and will promptly execute and deliver to ASSIGNEE or its legal representative(s) any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention(s) and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, the undersigned ASSIGNOR executed this assignment this 3rd day of June, at Pittsburgh, Pennsylvania, United States of America.

BAYER CORPORATION

{Corporate Seal}

By: _____
George J. Lykos
Senior Vice President, Chief Legal Officer
and Secretary



46
7

950

ATTACHMENT A


TITLE	Attorney Docket No.	AP. NO.	FILING DATE
RAF Kinase Inhibitors	Bayer 1	09/083,399	5/22/98
Inhibition of RAF Kinase Activity Using Aryl Ureas	Bayer 1 D1	09/755,060	1/8/01
RAF Kinase Inhibitors	Bayer 1V1	60/126,420	5/23/97
Inhibition of P38 Kinase Activity by Aryl Ureas	Bayer 2 V1	60/098,557	5/22/98
Inhibition of P38 Kinase Activity by Aryl Ureas	Bayer 2	08/863,022	5/23/97
Inhibition of P38 Kinase Activity by Aryl Ureas	Bayer 2 P1	09/083,396	5/22/97
Inhibition of P 38 Kinase Activity by Aryl Ureas	Bayer 2 D1	09/947,761	9/7/01
Inhibition of RAF Kinase Using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas	Bayer 6	08/996,344	12/22/97
Inhibition of RAF Kinase Using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas	Bayer 6 P1	09/776,936	12/22/98
Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas	Bayer 8	08/996,343	12/22/97
Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas	Bayer 8 C1	09/640,780	8/18/00
Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas	Bayer 8 P1	09/479,125	12/22/98
Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	Bayer 9	08/996,181	12/22/97
Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	Bayer 9 P1	09/303,621	12/22/98
Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	Bayer 9 C1	09/472,232	12/27/98




47

8


Inhibition of P 38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas	Bayer 10	08/995,749	12/22/97
Inhibition of P 38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas	Bayer 10 C1	09/458,015	12/10/99
Inhibition of P 38 Kinase Activity Using Symmetrical and Unsymmetrical Diphenyl Ureas	Bayer 10 C2	10/060,396	2/1/02
Inhibition of P 38 Kinase Using Substituted Heterocyclic Ureas	Bayer 11	08/995,750	12/22/97
Inhibition of P 38 Kinase Using Substituted Heterocyclic Ureas	Bayer 11 P1	09/285,521	12/22/98
Inhibition of P 38 Kinase Using Substituted Heterocyclic Ureas	Bayer 11 C1	09/458,014	12/10/99
Inhibition of P 38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	Bayer 12 V1	60/135,094	12/22/98
Inhibition of P 38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	Bayer 12	08/995,751	12/22/97
Inhibition of P 38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas	Bayer 12 P1	09/776,935	12/22/98
Inhibition of Raf Kinase Quinolinyl, Isoquinolinyl or Pyridyl Ureas	Bayer 13 V1	60/367,376	4/19/01
Inhibition of Raf Kinase Quinolinyl, Isoquinolinyl or Pyridyl Ureas	Bayer 13	09/838,285	4/20/01
Inhibition of Raf Kinase Quinolinyl, Isoquinolinyl or Pyridyl Ureas	Bayer 13A	10/125,369	4/19/02
Heteroaryl Ureas Containing Nitrogen Hetero-Atoms as P 38 Kinase Inhibitors	Bayer 14	09/838,286	4/20/01
Inhibition of p38 Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas	Bayer 15 V1	60/115,878	1/13/99



Inhibition of p38 Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas	Bayer 15	09/257,266	2/25/99
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 15 P1	09/425,228	10/22/99
Inhibition of Raf Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas	Bayer 15 V2	60/115,877	1/13/99
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 15 C1	09/948,915	9/10/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 15 A	09/889,227	7/12/01
Inhibition of RAF Kinase Using Quinolinyl, Isoquinolinyl and Pyridinyl Ureas	Bayer 15 P2	09/758,548	1/12/01
Inhibition of RAF Kinase Using Quinolinyl, Isoquinolinyl and Pyridinyl Ureas	Bayer 15 P3	09/777,920	2/7/01
Method and/or Process for Preparing ω-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors	Bayer 15 P4	10/071,248	2/11/02
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	Bayer 16	09/257,265	1/25/99
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	Bayer 16 P1	09/425,229	10/22/99
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	Bayer 16 P3	09/778,039	2/7/01
Omega-Carboxyaryl Substituted Diphenyl Urea as P 38 Kinase Inhibitors	Bayer 16 P4	10/071,248	2/11/02
Aryl Ureas with Angiogenisis Inhibiting Activity	Bayer 17	10/361,858	2/11/03




Aryl [illegible] with Angiogenisis Inhibiting Activity	Bayer 17 V1	60/354,950	2/11/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 18 V1	60/367,346	11/28/00
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 18	09/722,418	11/27/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 18A	09/993,647	11/27/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 19	09/773,675	2/2/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 20	09/773,659	2/2/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 21	09/773,659	2/2/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 22	09/773,658	2/2/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 23	09/773,672	2/2/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 24 V1	60/367,379	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 24	90/758,266	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 24A	09/758,266	1/11/02




50

ω-C[illegible]xyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 25 V1	60/367,380	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 25	09/758,547	1/12/01
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 25 C1	10/283,248	10/30/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 25A	10/042,203	1/11/02
ω-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase Inhibitors	Bayer 29	60/334,609	12/3/01
Rho-Kinase Inhibitors	Bayer 26 V1	60/349,987	1/23/02
Rho-Kinase Inhibitors	Bayer 26V2 5078 PROV	60/349,986	1/23/02
Rho-Kinase Inhibitors	Bayer 26-1	10/349,177	1/23/03
Rho-Kinase Inhibitors	Bayer-26-2 5078	10/349,176	1/23/03
Rho-Kinase Inhibitors	Bayer 27V1 5070 PROV	60/277,974	3/23/01
Rho-Kinase Inhibitors	Bayer 27V4 5070 PROV	60/315,338	8/29/01
Rho-Kinase Inhibitors	Bayer 27 V3	60/346,628	1/10/02
Rho-Kinase Inhibitors	Bayer 27-4 5130	10/103,565	3/22/02
Rho-Kinase Inhibitors	Bayer 27-3	10/339,393	1/10/03
ω-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors	Bayer 29	09/907,970	7/19/01
Process For Preparing Quinazoline Rho-Kinase Inhibitors And Intermediates Thereof	Bayer 30	10/252,369	9/30/02



51

Aryl Compounds in Combination with Other Cytostatic or Cytotoxic Agents for Treating Human Cancers	Bayer 34 V1	60/334,609	12/3/01
Aryl Urea Compounds in Combination with Other Cytostatic or Cytotoxic Agents for Treating Human Cancers	Bayer 34	10/308,187	12/3/02
Aryl Ureas as Raf Kinase Inhibitors	Bayer 35 V1	60/354,937	2/11/02
Aryl Ureas as Raf Kinase Inhibitors	Bayer 35	10/361,859	2/11/03
Aryl Ureas with RAF Kinase and Angiogenesis Inhibiting Activity	Bayer 36 V1	60/354,948	2/11/02
Aryl Ureas with RAF Kinase and Angiogenesis Inhibiting Activity	Bayer 36	10/361,844	2/11/03
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors	Bayer 37 V1	60/354,935	2/11/02
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors	Bayer 37	10/361,850	2/11/03
2-OXO-1,3,5-Perhydrotriazapine Derivatives Useful in the Treatment of Hyperproliferative Disorders	Bayer 42 V1	60/450,323	2/28/03
Substituted Pyridine Derivatives Useful in the Treatment of Cancer and Other Disorders	Bayer 43 V1	60/450,324	2/28/03
Novel Bicyclic Urea Derivatives Useful in the Treatment of Cancer and Other Disorders	Bayer 44 V1	60/450,348	2/28/03



Industria y Comercio
SUPERINTENDENCIA

LISTADO INFORMATIVO DE ANOTACIONES EN EL REGISTRO

22 – 10 - 2010

Las siguientes inscripciones de afectación fueron anotadas en el registro de la propiedad industrial en lo fechado, correspondiente a las siguientes patentes de invención y diseño industrial.

PATENTES DE INVENCION.

Transferencias:

1.

Expediente Nº	**00-1451**
Denominación de la invención:	**DIFENIL UREAS SUSTITUIDAS CON ω-CARBOXIARILO Y SUS SALES FARMACEUTICAMENTE ACEPTABLES COMO INHIBIDORES DE RAF QUINASA.**
Certificado:	**28604.**
De:	**BAYER CORPORATION., con domicilio en Pittsburg, Pennsylvania, Estados Unidos de América.**
A:	**BAYER HEALTHCARE LLC., con domicilio en Tarrytown, New York, Estados Unidos de América.**
Vigencia de la patente:	**13 de enero del 2020.**
Apoderada	**Dilia María Rodríguez D'Aleman.**

2.

Expediente Nº	**00-72226**
Denominación de la invención:	**PIRIDINAS Y PIRIDACINAS SUSTITUIDAS CON ACTIVIDAD DE INHIBICIÓN DE ANGIOGENESIS.**
Certificado:	**29090.**
De:	**BAYER CORPORATION., con domicilio en Pittsburg, Pennsylvania, Estados Unidos de América.**
A:	**BAYER HEALTHCARE LLC., con domicilio en Tarrytown, New York, Estados Unidos de América.**
Vigencia de la patente:	**22 de septiembre del 2020.**
Apoderada	**Luz Clemencia de Páez.**

Sede Centro: Carrera 13 No. 27-00 Pisos 2, 5, 7 y 10
Sede CAN: Tr. 40A No. 38-50 Conmutador: 5870000
Fax: 5870284. Línea 0180000-910165
Web: www.sic.gov.co e-mail: info@sic.gov.co
Bogotá D.C. - Colombia

937

Industria y Comercio
SUPERINTENDENCIA

LISTADO INFORMATIVO DE ANOTACIONES EN EL REGISTRO

22 – 10 - 2010

DISEÑO INDUSTRIAL.

Transferencia:

1.

Expediente Nº	**05-80907**
Denominación del registro de diseño:	**TOALLA DE PAPEL.**
Certificado:	**4981.**
De:	**KRUGER PRODUCTS LIMITED., con domicilio en Mississauga, Ontario, Canadá.**
A:	**KRUGER PRODUCTS L.P., con domicilio en Mississauga, Ontario, Canadá.**
Vigencia del registro:	**16 de agosto del 2015.**
Apoderada	**Luz Clemencia de Páez.**

PATENTE DE INVENCION.

Cambio de nombre:

1.

Expediente Nº	**01-34510**
Denominación de la invención:	**SUBTAPA O INSERTO CAPILAR PARA ENVASES GOTEROS.**
Certificado:	**28891.**
De:	**PRODUCTORES DE ENVASES FARMACEUTICOS S.A. PROENFAR S.A., con domicilio en Bogotá D.C., Cundinamarca, Colombia.**
Por:	**PRODUCTORES DE ENVASES FARMACEUTICOS S.A.S. PROENFAR S.A.S., con domicilio en Bogotá D.C., Cundinamarca, Colombia.**
Vigencia de la patente:	**03 de mayo del 2021.**
Representante legal	**Fernando Gustavo Medina Garavito.**

Las anteriores inscripciones se entienden notificadas en la fecha de la anotación, conforme a lo establecido en el artículo 44 del Código Contencioso Administrativo.

ALIX CARMENZA CESPEDES DE VERGEL
Directora de Nuevas Creaciones (C)

Sede Centro: Carrera 13 No. 27-00 Pisos 2, 5, 7 y 10
Sede CAN: Tr. 40A No. 38-50 Conmutador: 5870000
Fax: 5870284. Línea 0180000-910165
Web: www.sic.gov.co e-mail: info@sic.gov.co
Bogotá D.C. - Colombia